From Device Centric To Disease Management: Ascensia Commits To Deeper Role In Diabetes
Executive Summary
Ascensia is pushing back the borders of diabetes control, using its legacy BGM technology as a business platform to move into CGM en route to becoming a one-stop-shop for diabetes management solutions. A significant step toward these goals was taken in January, when the Swiss group completed a key China deal with a local CGM innovator, as chief marketing and strategy officer Martin Lange explained to In Vivo.
You may also be interested in...
When Will POC Really Be On The Cusp Of Major Uptake?
Point-of-care/near-patient testing has been “two years away from major breakthrough” for at least two decades, but fast access to data via automation and IT means that progress might change at last. How the tests are paid for remains an issue. The future of POC was the theme of an investor discussion at the first DxPx conference, held during the Medica 2019 event in Germany.
EU MDR Must Ensure Medtech Innovation Keeps Flowing, Say German MPs
For many, the EU MDR is coming too fast, yet several of its crucial elements are not yet in place. Germany’s liberal FDP MPs say the national government needs to make a stand and address a European issue that will impact German patients. In a motion to parliament, the MPs propose fast-tracking for innovative products and measures to keep orphan devices in circulation.
Formal UK Medical Devices Legislation Expected In Spring
The Queen’s speech last month signaled new legislation for medical devices after the UK leaves the umbrella of EU legislation, following the December election result. The bill is expected to enter its second reading in March 2020.
Need a specific report? 1000+ reports available
Buy Reports